|
|
Article: Abraxis cited for problems with labeling, aseptic conditions.(HUMAN DRUGS)
- Article from:
- Inspection Monitor
- Article date:
- October 1, 2008
CopyrightCOPYRIGHT 2008 Washington Information Source, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abraxis Pharmaceutical Products, Melrose Park, IL, Chicago District
Investigators Carrie Ann Plucinski and Russell Riley gave Abraxis a three-item 483 after an inspection of the drug manufacturer Aug. 23-Sept. 28, 2007.
The inspectors found that Abraxis approved and released for use labeling and packaging materials that did not meet written specifications. The firm labeled one lot of Octreotide Acetate Injection with vial labels that incorrectly stated the concentration of the drug as 0.05 mg/mL rather than 0.5 mg/mL. The company had recently changed its labels to add its new name and "LOT/EXP"; the concentration on the labels was inadvertently changed ...